Doxa AB (publ) (DOXA.ST)
SEK 0.35
(-0.29%)
SEK 0.35
(-0.29%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 9.9 Million SEK | 90.38% |
| 2022 | 5.2 Million SEK | -52.29% |
| 2021 | 10.9 Million SEK | 27.62% |
| 2020 | 8.54 Million SEK | -55.69% |
| 2019 | 19.27 Million SEK | -42.91% |
| 2018 | 33.75 Million SEK | 106.72% |
| 2017 | 16.33 Million SEK | -6.92% |
| 2016 | 17.54 Million SEK | 16.86% |
| 2015 | 15.01 Million SEK | 66.85% |
| 2014 | 8.99 Million SEK | 46.1% |
| 2013 | 6.15 Million SEK | 180.85% |
| 2012 | 2.19 Million SEK | 118.21% |
| 2011 | 1 Million SEK | 16.45% |
| 2010 | 863 Thousand SEK | 1661.22% |
| 2009 | 49 Thousand SEK | 880.0% |
| 2008 | 5000.00 SEK | -99.73% |
| 2007 | 1.82 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 4.6 Million SEK | -4.17% |
| 2024 Q1 | 4.8 Million SEK | 20.0% |
| 2023 Q1 | 1.1 Million SEK | -31.25% |
| 2023 FY | 9.9 Million SEK | 90.38% |
| 2023 Q2 | 1.3 Million SEK | 18.18% |
| 2023 Q4 | 4 Million SEK | 17.65% |
| 2023 Q3 | 3.4 Million SEK | 161.54% |
| 2022 Q1 | 500 Thousand SEK | -16.67% |
| 2022 FY | 5.2 Million SEK | -52.29% |
| 2022 Q4 | 1.6 Million SEK | 14.29% |
| 2022 Q3 | 1.4 Million SEK | -17.65% |
| 2022 Q2 | 1.7 Million SEK | 240.0% |
| 2021 FY | 10.9 Million SEK | 27.62% |
| 2021 Q2 | 3.9 Million SEK | 0.0% |
| 2021 Q3 | 2.5 Million SEK | -35.9% |
| 2021 Q4 | 600 Thousand SEK | -76.0% |
| 2021 Q1 | 3.9 Million SEK | 28.25% |
| 2020 Q1 | 3.4 Million SEK | -50.54% |
| 2020 Q3 | 1.4 Million SEK | 100.0% |
| 2020 Q2 | 700 Thousand SEK | -79.41% |
| 2020 Q4 | 3.04 Million SEK | 117.21% |
| 2020 FY | 8.54 Million SEK | -55.69% |
| 2019 Q4 | 6.87 Million SEK | 96.4% |
| 2019 FY | 19.27 Million SEK | -42.91% |
| 2019 Q3 | 3.5 Million SEK | -16.67% |
| 2019 Q2 | 4.2 Million SEK | -10.64% |
| 2019 Q1 | 4.7 Million SEK | -5.2% |
| 2018 FY | 33.75 Million SEK | 106.72% |
| 2018 Q4 | 4.95 Million SEK | 5.49% |
| 2018 Q3 | 4.7 Million SEK | -77.73% |
| 2018 Q1 | 3.1 Million SEK | -41.84% |
| 2018 Q2 | 21.1 Million SEK | 580.65% |
| 2017 FY | 16.33 Million SEK | -6.92% |
| 2017 Q3 | 3.4 Million SEK | -8.11% |
| 2017 Q2 | 3.7 Million SEK | -5.13% |
| 2017 Q1 | 3.9 Million SEK | -21.12% |
| 2017 Q4 | 5.33 Million SEK | 56.76% |
| 2016 Q3 | 4 Million SEK | -21.57% |
| 2016 Q2 | 5.1 Million SEK | 45.71% |
| 2016 Q4 | 4.94 Million SEK | 23.6% |
| 2016 FY | 17.54 Million SEK | 16.86% |
| 2016 Q1 | 3.5 Million SEK | -14.9% |
| 2015 FY | 15.01 Million SEK | 66.85% |
| 2015 Q4 | 4.11 Million SEK | 24.64% |
| 2015 Q3 | 3.3 Million SEK | -23.26% |
| 2015 Q2 | 4.3 Million SEK | 30.3% |
| 2015 Q1 | 3.3 Million SEK | 13.87% |
| 2014 Q3 | 2.1 Million SEK | 0.0% |
| 2014 Q1 | 1.9 Million SEK | 38.18% |
| 2014 Q2 | 2.1 Million SEK | 10.53% |
| 2014 Q4 | 2.89 Million SEK | 38.0% |
| 2014 FY | 8.99 Million SEK | 46.1% |
| 2013 Q4 | 1.37 Million SEK | -14.06% |
| 2013 Q1 | 1.5 Million SEK | 1823.08% |
| 2013 FY | 6.15 Million SEK | 180.85% |
| 2013 Q3 | 1.6 Million SEK | -5.88% |
| 2013 Q2 | 1.7 Million SEK | 13.33% |
| 2012 Q4 | 78 Thousand SEK | 0.0% |
| 2012 FY | 2.19 Million SEK | 118.21% |
| 2011 FY | 1 Million SEK | 16.45% |
| 2010 FY | 863 Thousand SEK | 1661.22% |
| 2009 FY | 49 Thousand SEK | 880.0% |
| 2008 FY | 5000.00 SEK | -99.73% |
| 2007 FY | 1.82 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AddLife AB (publ) | 9.68 Billion SEK | 99.898% |
| Biotage AB (publ) | 1.86 Billion SEK | 99.468% |
| Bonesupport Holding AB (publ) | 591.07 Million SEK | 98.325% |
| Elekta AB (publ) | 18.11 Billion SEK | 99.945% |
| iZafe Group AB (publ) | 1.82 Million SEK | -443.359% |
| Ortivus AB (publ) | 84.08 Million SEK | 88.226% |
| Ortivus AB (publ) | 84.08 Million SEK | 88.226% |
| Q-linea AB (publ) | 4.44 Million SEK | -122.973% |
| S2Medical AB (publ) | 6.97 Million SEK | -42.01% |
| Synsam AB (publ) | 5.9 Billion SEK | 99.832% |